ARTA
RNAC icon

A.R.T. Advisors’s Cartesian Therapeutics RNAC Stock Holding History

A.R.T. Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-739
Closed -$40K – 1689
2019
Q2 		$40K Buy
+739
New +$50.4K ﹤0.01% 1260
2019
Q1 		– Sell
-1,311
Closed -$105K – 1563
2018
Q4 		$105K Buy
1,311
+863
+193% +$197K 0.01% 1159
2018
Q3 		$208K Sell
448
-157
-26% -$63.1K 0.01% 1177
2018
Q2 		$240K Sell
605
-1,381
-70% -$490K 0.01% 1179
2018
Q1 		$607K Buy
1,986
+1,376
+226% +$392K 0.02% 871
2017
Q4 		$179K Buy
+610
New +$267K 0.01% 1189

Other funds holding RNAC

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

A.R.T. Advisors's RNAC Position: Q3 2019 in Review

A.R.T. Advisors sold out of Cartesian Therapeutics (RNAC) in Q3 2019, closing a stake of 739 shares — an estimated $40K sold.

A.R.T. Advisors first reported a position in RNAC in Q4 2017 and held it in 6 quarters. The position peaked at $607K in Q1 2018. 36 funds tracked by Wall St. Rank hold RNAC as of Q3 2019.

  • A.R.T. Advisors reported no remaining Cartesian Therapeutics position as of Q3 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 739 Cartesian Therapeutics shares in Q3 2019, an estimated $40K.
  • A.R.T. Advisors first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 6 quarters.
  • A.R.T. Advisors's Cartesian Therapeutics position peaked at $607K in Q1 2018.
  • 36 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.